Savara (SVRA) Interest Expenses (2011 - 2018)
Savara (SVRA) reported Interest Expenses of $113000.0 for Q2 2018, down 78.1% year-over-year from $516000.0 in Q2 2017, and up 8.65% on a QoQ basis from $104000.0 in Q1 2018.
Savara (SVRA) has 6 years of Interest Expenses data on file, last reported at $113000.0 in Q2 2018.
- Quarterly Interest Expenses fell 78.1% year-over-year to $113000.0 in Q2 2018, while the trailing twelve-month figure through Mar 2019 was $113000.0 (down 88.92% YoY) and the FY2017 annual result came in at $1.2 million, up 156.86% from the prior year.
- Interest Expenses rose to $113000.0 in Q2 2018 per SVRA's latest filing, from $104000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $2.5 million in Q4 2015 and bottomed at $1000.0 in Q2 2015.
- The 4-year median for Interest Expenses is $190000.0 (2016), against an average of $378769.2.
- The widest annual swing landed in 2016, when Interest Expenses slumped 90.13%; it then soared 7271.43% in 2017.
- Tracing SVRA's Interest Expenses over 4 years: stood at $2.5 million in 2015, then tumbled by 90.13% to $245000.0 in 2016, then slumped by 49.8% to $123000.0 in 2017, then dropped by 8.13% to $113000.0 in 2018.
- Per Business Quant, the three latest SVRA Interest Expenses figures stand at $113000.0 (Q2 2018), $104000.0 (Q1 2018), and $123000.0 (Q4 2017).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 113,000.00 |
| Jun 30, 2018 | 113,000.00 |
| Mar 31, 2018 | 104,000.00 |
| Mar 31, 2018 | 104,000.00 |
| Dec 31, 2017 | 123,000.00 |
| Dec 31, 2017 | 123,000.00 |
| Sep 30, 2017 | 277,000.00 |
| Sep 30, 2017 | 277,000.00 |
| Jun 30, 2017 | 516,000.00 |
| Jun 30, 2017 | 516,000.00 |
| Mar 31, 2017 | 245,000.00 |
| Mar 31, 2017 | 245,000.00 |
| Dec 31, 2016 | 245,000.00 |
| Dec 31, 2016 | 245,000.00 |
| Sep 30, 2016 | 190,000.00 |
| Sep 30, 2016 | 190,000.00 |
| Jun 30, 2016 | 7,000.00 |
| Jun 30, 2016 | 7,000.00 |
| Mar 31, 2016 | 519,000.00 |
| Mar 31, 2016 | 519,000.00 |
| Dec 31, 2015 | 2.48 Mn |
| Dec 31, 2015 | 2.48 Mn |
| Sep 30, 2015 | 101,000.00 |
| Sep 30, 2015 | 101,000.00 |
| Jun 30, 2015 | 1,000.00 |
| Jun 30, 2015 | 1,000.00 |
| Mar 31, 2012 | 10,710.00 |
| Mar 31, 2012 | 10,710.00 |
| Dec 31, 2011 | 10,738.00 |
| Dec 31, 2011 | 10,738.00 |
| Sep 30, 2011 | 272.00 |
| Sep 30, 2011 | 272.00 |